Early in differentiation, a subset of the RFP + cells expressed the erythroid progenitor cell marker CD36 (ref. 9) and CD41, the earliest marker of hematopoietic progenitors in differentiating ...

Virtual event with Key Opinion Leaders to discuss cell therapy landscape and shortcomings of CAR-T therapies set for May 28, 2025HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC.

--Marker Therapeutics, Inc., a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological ...